RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1005 participants.
Also called NCT02303795
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 1,005 participants
- Sponsor
- Registry
-
NCT02303795
-
- Other papers using this trial's data
- Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Brazil
- Registry status
- Completed
Technical summary
Registry record NCT02303795. Randomized; no masking; primary purpose treatment. Start 2015-08 (actual); primary completion 2020-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial
- Condition
- Valvular Heart Disease
- Intervention (Drug)
- Rivaroxaban
- Intervention (Drug)
- Warfarin
- Lead sponsor
- Hospital do Coracao
Record details
- Record id
cardio:ct-nct02303795- Content hash
a33cc0708b2581e8280eaeea571f068e8300cfb720c55525834631f0568d8595